Compare Abeona Therapeutics Inc (ABEO) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Taskus Inc — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Taskus Inc trades at $5.12 (market cap $475.98M). The key difference: Taskus Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | TASK | |
|---|---|---|
Market Cap | $373.32M | $475.98M |
Sector | Health | Technology |
52-Week High | $7.23 | $18.21 |
52-Week Low | $4.17 | $4.57 |
Enterprise Value | $228.22M | $871.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TaskUs trades at $5.19, up 3.18% today, with a bearish technical signal despite strong fundamentals including a P/E of 4.59 and net income margin of 8.7%. Recent Q1 2026 earnings missed expectations, but revenue reached $1.18B in 2025. The company appointed a new CFO in June 2026 and reported growing interest in robotaxi services, indicating strategic positioning in digital customer experience.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. Risks include recent earnings volatility and competitive pressures in outsourcing services. Analyst sentiment is mixed with 55% buy ratings, suggesting cautious optimism amid near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
